Korea United Pharma succeed in registering ‘Cilostan CR’ in foreign countries
Korea United Pharma(CEO Duk-young Kang) acquired product approval of ‘Cilostan CR,’ an incrementally modified drug, from the Philippine Food and Drug Administration(PFDA).
Cilostan CR Tab, an incrementally modified antithrombotic drug launched in 2013 after its 5-year R&D program, is a product...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
